Submit manuscript

The Efficacy and Safety of Lyophilized Cryoprecipitate in Hemophilia A

AMPAIWAN CHUANSUMRIT, M.D.*, PARTTRAPORN ISARANGKURA, M.D., D.Sc.*, AROONRAT CHANTANAKAJORNFUNG, B.Sc.**, KESANEE KUHATHONG, B.Sc.*, PAKAIMAS PINTADIT, B.Sc. *, CHATTA Y A JITPRAPHAI, M.D.*, PHONGJAN HATHIRAT,M.D.*, CHAIVEJ NUCHPRAYOON,M.D.**

Affiliation : * International Hemophilia Training Center-Bangkok, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, ** National Blood Center, Thai Red Cross Society, Bangkok 10330, Thailand.

Abstract
This prospective study of assessing the efficacy and safety of lyophilized cryoprecipitate (LC), which was heat-treated at 60°C for 25 hours, was conducted in 23 patients with hemophilia A (severe 13, moderate 9, mild 1) at the International Hemophilia Training Center, Bangkok from 1997 to 1998. A total of 223 infusions of LC were given. The status of the patients could be classified into 4 groups : group I, non-bleeding (n = 13); group II, severe bleeding requiring hos- pitalization (n = 9); group III, appendectomy (n = 1) and group IV, early bleeding controlled by modified home treatment (n = 200). Pharmacokinetic studies were conducted in groups I and II. The mean in vivo half-life of factor VIII clotting activity (F VIII:C) was 12.6 hours and the mean in vivo incremental recovery at baseline was 2.1 per cent/unit/kg. The mean clearance was 3.22 mVkglh. There was no statistically significant difference in these parameters between groups I and II (p > 0.05). The hemostasis was successfully achieved and 1 to 2 small urticarial wheals were observed in only 2 infusions. In addition, 9 out of 23 patients received LC exclusively for 1 year. None of them developed inhibitor to F VIII:C nor did any contract additional trans- fusion-transmitted infection except one who developed anti-hepatitis C virus seroconversion after receiving 16 bottles of LC in 4 months. Therefore, the more efficient virus-inactivation in the preparation of LC should be established.

Keywords : Lyophilized Cryoprecipitate, Hemophilia, Efficacy, Safety


All Articles Download


INFORMATION

Contact info

JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
4th Floor, Royal Golden Jubilee Building,
2 Soi Soonvijai, New Petchburi road,
Bangkok 10310, Thailand.
Phone: 0-2716-6102, 0-2716-6962
Fax: 0-2314-6305
Email: editor@jmatonline.com

JMed Assoc Thai
MEDICAL ASSOCIATION OF THAILAND
ISSN: 0125-2208 (Print),
ISSN: 2408-1981 (Online)
The content of this site is intended for health professionals.

Submissions

» Online Submissions » Author Guidelines » Copyright Notice » Privacy Statement

Other

» Journal Sponsorship » Site Map » About this Publishing System

© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.